A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 5, 2017, Pages 1378-1387.e5

  Usmani, Omar S ^a,b   Kemppinen, Anu ^c,d   Gardener, Elizabeth ^e   Thomas, Vicky ^e   Konduru, Priyanka Raju ^e   Callan, Christina ^c,d   McLoughlin, Andrew ^c,d   Woodhead, Vanessa ^c,d   Brady, Adam ^d   Juniper, Elizabeth F ^f   Barnes, Peter J ^a,b   Price, David ^c,g,h  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Research in Real Life Ltd   (United Kingdom)

^d Optimum Patient Care Ltd   (United Kingdom)

^e Cambridge Architectural Research Ltd   (United Kingdom)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

^h OBSERVATIONAL AND PRAGMATIC RESEARCH INSTITUTE   (Singapore)

Author keywords

ACQ7; Antiasthmatic agents; Biomarkers; Combination therapy; Fluticasone; Formoterol; Fractional exhaled nitric oxide; Inhaled corticosteroids; Pragmatic trials; Salmeterol; Step down

Indexed keywords

FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; BRONCHODILATING AGENT; FLUTICASONE; FORMOTEROL FUMARATE; SALMETEROL XINAFOATE;

ADULT; AGED; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CLINICAL PROTOCOL; DRUG COMBINATION; MIDDLE AGED; QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL PROTOCOLS; DRUG COMBINATIONS; FEMALE; FLUTICASONE; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SALMETEROL XINAFOATE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 85016022374     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2017.02.006     Document Type: Article

References (29)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2016. Available from: http://ginasthma.org/gina-reports/. Accessed August 15, 2016.
2. O'Byrne, P.M., Reddel, H.K., Colice, G.L., Does the current stepwise approach to asthma pharmacotherapy encourage over-treatment?. Respirology 15 (2010), 596–602.
3. Thomas, M., von Ziegenweidt, J., Lee, A.J., Price, D., High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol 123 (2009), 116–121.
4. Hawkins, G., McMahon, A.D., Twaddle, S., Wood, S.F., Ford, I., Thomson, N.C., Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ, 326, 2003, 1115.
5. Horiuchi, K., Kasahara, K., Kuroda, Y., Morohoshi, H., Hagiwara, Y., Ishii, G., Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy. J Asthma Allergy 9 (2016), 65–70.
6. Papi, A., Nicolini, G., Crimi, N., Fabbri, L., Olivieri, D., Rossi, A., et al. Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respir Res, 13, 2012, 54.
7. Koenig, S.M., Ostrom, N., Pearlman, D., Waitkus-Edwards, K., Yancey, S., Prillaman, B.A., et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are “stepped-down.”. J Asthma 45 (2008), 681–687.
8. Hagan, J.B., Samant, S.A., Volcheck, G.W., Li, J.T., Hagan, C.R., Erwin, P.J., et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy 69 (2014), 510–516.
9. Gionfriddo, M.R., Hagan, J.B., Hagan, C.R., Volcheck, G.W., Castaneda-Guarderas, A., Rank, M.A., Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma: systematic review and meta-analysis. Allergy Asthma Proc 36 (2015), 262–267.
10. Hoffmann, H.J., Nielsen, L.P., Harving, H., Heinig, J.H., Dahl, R., Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Clin Respir J 2 (2008), 149–157.
11. Leuppi, J.D., Salome, C.M., Jenkins, C.R., Anderson, S.D., Xuan, W., Marks, G.B., et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 163 (2001), 406–412.
12. Tsurikisawa, N., Oshikata, C., Tsuburai, T., Mitsui, C., Tanimoto, H., Takahashi, K., et al. Markers for step-down of inhaled corticosteroid therapy in adult asthmatics. Allergol Int 61 (2012), 419–429.
13. Calhoun, W.J., Ameredes, B.T., King, T.S., Icitovic, N., Bleecker, E.R., Castro, M., et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 308 (2012), 987–997.
14. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2012. Available from: www.ginasthma.org. Accessed December 2, 2013. [This report is no longer available online].
15. Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999), 902–907.
16. Juniper, E.F., Guyatt, G.H., Cox, F.M., Ferrie, P.J., King, D.R., Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 14 (1999), 32–38.
17. Ohta, K., Jean Bousquet, P., Akiyama, K., Adachi, M., Ichinose, M., Ebisawa, M., et al. Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan. J Asthma 50 (2013), 514–521.
18. Ciprandi, G., Schiavetti, I., Sorbello, V., Ricciardolo, F.L., Perception of asthma symptoms as assessed on the visual analog scale in subjects with asthma: a real-life study. Respir Care 61 (2016), 23–29.
19. Dweik, R.A., Boggs, P.B., Erzurum, S.C., Irvin, C.G., Leigh, M.W., Lundberg, J.O., et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184 (2011), 602–615.
20. Khalili, B., Boggs, P.B., Bahna, S.L., Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 62 (2007), 1171–1174.
21. Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999), 109–117.
22. Clearie, K.L., Jackson, C.M., Fardon, T.C., Williamson, P.A., Vaidyanathan, S., Burns, P., et al. Supervised step-down of inhaled corticosteroids in the community—an observational study. Respir Med 105 (2011), 558–565.
23. Price, D., Chisholm, A., Hillyer, E.V., Burden, A., von Ziegenweidt, J., Svedsater, H., et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. J Allergy Ther, 4, 2013, 1.
24. Rank, M.A., Johnson, R., Branda, M., Herrin, J., van Houten, H., Gionfriddo, M.R., et al. Long-term outcomes after stepping down asthma controller medications: a claims-based, time-to-event analysis. Chest 148 (2015), 630–639.
25. Crim, C., Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34 (2009), 641–647.
26. Calverley, P.M., Stockley, R.A., Seemungal, T.A., Hagan, G., Willits, L.R., Riley, J.H., et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 139 (2011), 505–512.
27. European Medicines Agency; Pharmacovigilance Risk Assessment Committee. Assessment report EMA/330021/2016. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Inhaled_corticosteroids_Article_31/European_Commission_final_decision/WC500210491.pdf. Accessed August 15, 2016.
28. O'Byrne, P.M., Pedersen, S., Carlsson, L.G., Radner, F., Thorén, A., Peterson, S., et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 183 (2011), 589–595.
29. Ernst, P., Suissa, S., Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med 18 (2012), 85–89.